Sol-Gel Technologies (SLGL) Liabilities and Shareholders Equity (2016 - 2026)
Sol-Gel Technologies (SLGL) reported Liabilities and Shareholders Equity of $58.6 million for Q1 2026, up 116.35% year-over-year from $27.1 million in Q1 2025, and up 95.71% quarter-over-quarter from $29.9 million in Q4 2025.
Sol-Gel Technologies (SLGL) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $58.6 million in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $58.6 million, up 116.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $162.4 million (up 9.79% YoY), and the FY2025 annual result was $29.9 million, down 16.54% from the prior year.
- Liabilities and Shareholders Equity advanced to $58.6 million in Q1 2026 per SLGL's latest filing, from $29.9 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $58.6 million in Q1 2026 and troughed at $27.1 million in Q1 2025.
- A 5-year average of $44.6 million and a median of $45.3 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity slumped 32.61% in 2022, then jumped 116.35% in 2026.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $46.6 million in 2022, then retreated by 2.88% to $45.3 million in 2023, then dropped by 20.85% to $35.8 million in 2024, then fell by 16.54% to $29.9 million in 2025, then soared by 95.71% to $58.6 million in 2026.
- Business Quant data shows SLGL's Liabilities and Shareholders Equity at $58.6 million in Q1 2026, $29.9 million in Q4 2025, and $34.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 58.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.55 Mn |
| Dec 31, 2025 | 29.92 Mn |
| Sep 30, 2025 | 34.59 Mn |
| Jun 30, 2025 | 39.31 Mn |
| Mar 31, 2025 | 27.06 Mn |
| Dec 31, 2024 | 35.85 Mn |
| Sep 30, 2024 | 42.98 Mn |
| Jun 30, 2024 | 42.01 Mn |
| Mar 31, 2024 | 39.91 Mn |
| Dec 31, 2023 | 45.29 Mn |
| Sep 30, 2023 | 49.86 Mn |
| Jun 30, 2023 | 55.10 Mn |
| Mar 31, 2023 | 49.04 Mn |
| Dec 31, 2022 | 46.63 Mn |
| Sep 30, 2022 | 51.29 Mn |
| Jun 30, 2022 | 54.98 Mn |
| Mar 31, 2022 | 56.06 Mn |
| Dec 31, 2021 | 69.19 Mn |
| Sep 30, 2021 | 52.83 Mn |
| Jun 30, 2021 | 46.41 Mn |